Related Experiment Video

Updated: Apr 5, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K

Emerging drugs in refractory colorectal cancer

Stefania Nobili1, Alessandro Galletta1, Marco Brugia2

  • 1Section of Clinical Pharmacology & Oncology, Department of Health Sciences, University of Florence, viale Pieraccini, 6 - 50139 Florence, Italy.

Future Medicinal Chemistry
|August 22, 2015
PubMed

Insights

Drug resistance in metastatic colorectal cancer (CRC) leads to poor outcomes. New strategies like targeted inhibitors, epigenetic resensitization, and drug combinations aim to overcome treatment resistance in CRC patients.

Area of Science:

  • Oncology
  • Cancer Therapeutics
  • Molecular Biology

Background:

  • Colorectal cancer (CRC) is a leading cause of cancer mortality globally.
  • Metastatic CRC (mCRC) patients often face poor prognoses due to tumor drug resistance.
  • Genetic and epigenetic alterations are key drivers of drug resistance in CRC.

Purpose of the Study:

  • To review current and emerging strategies for overcoming drug resistance in metastatic colorectal cancer.
  • To discuss novel therapeutic approaches for chemorefractory mCRC.
  • To explore clinical trial data on advanced treatment strategies for mCRC.

Main Methods:

  • Review of literature on mechanisms of drug resistance in colorectal cancer.
  • Analysis of therapeutic strategies including targeted inhibitors, epigenetic modifiers, and drug combinations.
  • Discussion of clinical trials evaluating novel treatments for mCRC post-first-line therapy.

Main Results:

  • Tumor drug resistance in mCRC is driven by genetic and epigenetic changes, leading to treatment failure.
  • Promising strategies include selective inhibitors, epigenetic resensitization, and novel cytotoxic agents.
  • Drug combinations and exploitation of synthetic lethality offer potential for improved efficacy.

Conclusions:

  • Overcoming drug resistance is critical for improving outcomes in metastatic colorectal cancer.
  • Targeted therapies, epigenetic reprogramming, and innovative drug combinations represent key future directions.
  • Clinical trials are essential to validate these strategies in patients with refractory mCRC.

More Related Videos

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

7.1K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

6.1K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
643
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68